ArticleClinical infectious diseases : an official publication of the Infectious Diseases Society of America2015
Public Health Impact After the Introduction of PsA-TT: The First 4 Years.
Article in Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Meningococcal serogroups and surveillance: a systematic review and survey.Journal of global health · 2019Pooled it
- Trial
- Meningitis in Niger Republic amidst COVID-19: current issues and novel recommendations.Annals of medicine and surgery (2012) · 2024Review
- Analysis of immunogenicity and purification methods in conjugated polysaccharide vaccines: a new approach in fighting pathogenic bacteria.Frontiers in immunology · 2024Review
- High-spatial resolution epidemic surveillance of bacterial meningitis in the African meningitis belt in Burkina Faso.Scientific reports · 2022Article
- 'Learn from the lessons and don't forget them': identifying transferable lessons for COVID-19 from meningitis A, yellow fever and Ebola virus disease vaccination campaigns.BMJ global health · 2021Review
- The effect of recombination on the evolution of a population ofGenome research · 2021Article
- Neisseria meningitidis: using genomics to understand diversity, evolution and pathogenesis.Nature reviews. Microbiology · 2020Review
- Atmospheric Dust, Early Cases, and Localized Meningitis Epidemics in the African Meningitis Belt: An Analysis Using High Spatial Resolution Data.Environmental health perspectives · 2018Article
- Acquisition of virulence genes by a carrier strain gave rise to the ongoing epidemics of meningococcal disease in West Africa.Proceedings of the National Academy of Sciences of the United States of America · 2018Article
- A world without bacterial meningitis: how genomic epidemiology can inform vaccination strategy.F1000Research · 2018Review
- Increase of Neisseria meningitidis W:cc11 invasive disease in Chile has no correlation with carriage in adolescents.PloS one · 2018Article
- The association between respiratory tract infection incidence and localised meningitis epidemics: an analysis of high-resolution surveillance data from Burkina Faso.Scientific reports · 2017Article
- Impact of introduction of rapid diagnostic tests for malaria on antibiotic prescribing: analysis of observational and randomised studies in public and private healthcare settings.BMJ (Clinical research ed.) · 2017Article
- Medicines Regulation in Africa: Current State and Opportunities.Pharmaceutical medicine · 2017Article
- Household transmission of Neisseria meningitidis in the meningitis belt.The Lancet. Global health · 2016Article
- Bacterial agents causing meningitis during 2013-2014 in Turkey: A multi-center hospital-based prospective surveillance study.Human vaccines & immunotherapeutics · 2016Observational
- Documenting the Results of a Successful Partnership: A New Meningococcal Vaccine for Africa.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
20 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundDuring the first introduction of a group A meningococcal vaccine (PsA-TT) in 2010-2011 and its rollout from 2011 to 2013, >150 million eligible people, representing 12 hyperendemic meningitis countries, have been vaccinated.
methodsThe new vaccine effectiveness evaluation framework was established by the World Health Organization and partners. Meningitis case-based surveillance was strengthened in PsA-TT first-introducer countries, and several evaluation studies were conducted to estimate the vaccination coverage and to measure the impact of vaccine introduction on meningococcal carriage and disease incidence.
resultsPsA-TT implementation achieved high vaccination coverage, and results from studies conducted showed significant decrease of disease incidence as well as significant reduction of oropharyngeal carriage of group A meningococci in vaccinated and unvaccinated individuals, demonstrating the vaccine's ability to generate herd protection and prevent group A epidemics.
conclusionsLessons learned from this experience provide useful insights in how to guide and better prepare for future new vaccine introductions in resource-limited settings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.